The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.

A nasal spray therapy for treatment-resistant major depressive disorder (MDD) has now been approved by the Food and Drug Administration (FDA) for use on its own, making it the first-ever approved ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

For people with anxiety and depression, these conditions can feel like two sides of the same coin. Researchers are exploring ...

Even light-intensity activities such as walking can reduce one’s risk for clinical depression. So, what are the most common ...

Using computational models, the researchers studied how the brain’s reward-learning system functions in those with depression ...